跳至主要内容
临床试验/IRCT20171225038073N1
IRCT20171225038073N1招募中3 期

Evaluation of nephroprotective effects of Melatonin in cancer patients treated with Cisplatin

Tehran University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • = 18 years of age
  • Cancer patients who receive Cisplatin with =50 mg/m2 of dose in one day and the chemotherapy courses are repeated every 3 weeks
  • Patients who do not use other nephrotoxic chemotherapy drugs
  • Glomerular filtration rate (GFR)>45 ml/min (modification of diet in renal disease (MDRD) formula)
  • Patients with one of lung? head and neck? genitourinary system, gastrointestinal cancers
  • Karnofsky status = 60%
  • Normal liver function

排除标准

  • Kidney cancer
  • Inability to take oral medication
  • Heart failure
  • Active infection
  • The history of using other nephrotoxic drugs (e.g. Vancomycin, Aminoglycoside, Amphotericin and NSAID) within the previous 2 weeks
  • The patients who are using angiotensin-converting-enzyme inhibitor (ACE inhibitor) & angiotensin receptor blockers (ARB) medicines

研究者

相似试验